AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
2min chapter
#60 – Going MAD for Non-COVID ID Literature: A Year in Review LIVE from MAD-ID
Breakpoints
Deloro Back-Damned: A Novel Beta Lactamase Inhibitor
The next late breaker that they presented at Ekma 2022 was the attack trial. The attack trial evaluated so back-damned Alora back-dam versus Callistin in patients with Asinita bermani I have that or bloodstream infection. Now our dear friend Jason Pope already gave away the punchline in his fabulous stock yesterday but alas I'm going to go through these data anyway because this is good stuff. Deloro back-dam is a novel beta lactamase inhibitor that inhibits class A, class C and class D beta lactamases.
00:00
Transcript
Episode notes
Get the Snipd
podcast app
Unlock the knowledge in podcasts with the podcast player of the future.
AI-powered
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode
Save any
moment
Hear something you like? Tap your headphones to save it with AI-generated key takeaways
Share
& Export
Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more
AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode